Q-omics provides the consensus-scored NFE2L3 profile across patient tissues and cancer cell-line models. NFE2L3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NFE2L3 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, NFE2L3 RNA expression shows 19,624 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where NFE2L3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NFE2L3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NFE2L3 survival associations across molecular data types. NFE2L3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NFE2L3 RNA expression–survival associations across cancer types. High NFE2L3 expression shows unfavorable associations in KIRP, ACC, MESO and PAAD, but favorable associations in STAD and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for NFE2L3 RNA expression.
This table summarizes NFE2L3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NFE2L3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NFE2L3 shows higher tumor expression in KIRC, THCA, COAD, HNSC, STAD and LUAD. The KIRC box plot shows higher NFE2L3 RNA expression in tumor versus normal tissue (log2 FC = +1.622, t-test p < 0.001).
This table shows molecular features associated with NFE2L3 in patient tissues and cancer cell lines. In patient samples, NFE2L3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NFE2L3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
